Combining venetoclax with a BTK inhibitor, an anti-CD20 monoclonal antibody, or a dual SYK/JAK inhibitor has shown promise in being able to overcome microenvironment-mediated resistance in CLL and MCL [103,104]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.